🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the pathogen, according to health experts.

A Global Health Concern

The sexually transmitted infection are escalating around the world, with figures suggesting more than 82 million infections per year. Especially elevated rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a all-time high, while figures across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune step in the context of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Health officials are increasingly worried about the rise in antibiotic-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance revealed that resistance to key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Drugs Secure Clearance

One new antibiotic, also known as a brand name, was authorized by the US Food and Drug Administration in December for use against gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that specific application of this new drug will help hinder the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This medication, which is employed against urinary tract infections, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone marks a huge turning point in the therapy of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Results and Global Access

As per findings detailed in a prominent scientific publication, zoliflodacin successfully treated more than 90% of cases of the STI. This places it at an similar efficacy with the typical regimen, which combines two antibiotics. The trial included hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in numerous developing nations.

Doctors treating patients have expressed hope. The availability of a one-pill regimen such as this is described as a "revolutionary step" for gonorrhoea control. This is deemed essential to reduce the burden of the disease for people and to halt the transmission of highly drug-resistant gonorrhoea around the world.